Cargando…
Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence from preclinical and clinical...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579520/ https://www.ncbi.nlm.nih.gov/pubmed/37015772 http://dx.doi.org/10.1136/jnnp-2021-328323 |
_version_ | 1785121741619593216 |
---|---|
author | Park, Susanna B Cetinkaya-Fisgin, Aysel Argyriou, Andreas A Höke, Ahmet Cavaletti, Guido Alberti, Paola |
author_facet | Park, Susanna B Cetinkaya-Fisgin, Aysel Argyriou, Andreas A Höke, Ahmet Cavaletti, Guido Alberti, Paola |
author_sort | Park, Susanna B |
collection | PubMed |
description | Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence from preclinical and clinical work on the onset, progression and outcome of axonal degeneration in CIPN. We review likely triggers of axonal degeneration in CIPN and highlight evidence of molecular pathways involved in axonal degeneration and their relevance to CIPN, including SARM1-mediated axon degeneration pathway. We identify potential clinical markers of axonal dysfunction to provide early identification of toxicity as well as present potential treatment strategies to intervene in axonal degeneration pathways. A greater understanding of axonal degeneration processes in CIPN will provide important information regarding the development and progression of axonal dysfunction more broadly and will hopefully assist in the development of successful interventions for CIPN and other neurodegenerative disorders. |
format | Online Article Text |
id | pubmed-10579520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-105795202023-10-18 Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence Park, Susanna B Cetinkaya-Fisgin, Aysel Argyriou, Andreas A Höke, Ahmet Cavaletti, Guido Alberti, Paola J Neurol Neurosurg Psychiatry Neuro-Oncology Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence from preclinical and clinical work on the onset, progression and outcome of axonal degeneration in CIPN. We review likely triggers of axonal degeneration in CIPN and highlight evidence of molecular pathways involved in axonal degeneration and their relevance to CIPN, including SARM1-mediated axon degeneration pathway. We identify potential clinical markers of axonal dysfunction to provide early identification of toxicity as well as present potential treatment strategies to intervene in axonal degeneration pathways. A greater understanding of axonal degeneration processes in CIPN will provide important information regarding the development and progression of axonal dysfunction more broadly and will hopefully assist in the development of successful interventions for CIPN and other neurodegenerative disorders. BMJ Publishing Group 2023-11 2023-04-04 /pmc/articles/PMC10579520/ /pubmed/37015772 http://dx.doi.org/10.1136/jnnp-2021-328323 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Neuro-Oncology Park, Susanna B Cetinkaya-Fisgin, Aysel Argyriou, Andreas A Höke, Ahmet Cavaletti, Guido Alberti, Paola Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence |
title | Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence |
title_full | Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence |
title_fullStr | Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence |
title_full_unstemmed | Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence |
title_short | Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence |
title_sort | axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence |
topic | Neuro-Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579520/ https://www.ncbi.nlm.nih.gov/pubmed/37015772 http://dx.doi.org/10.1136/jnnp-2021-328323 |
work_keys_str_mv | AT parksusannab axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence AT cetinkayafisginaysel axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence AT argyriouandreasa axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence AT hokeahmet axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence AT cavalettiguido axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence AT albertipaola axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence |